Investor Presentaiton

Private large portfolio companies EXTERNALLY VALUED RETAIL (PHARMACY) BUSINESS OVERVIEW (CONT'D) REVENUE AVERAGE BILL SIZE & NUMBER OF BILLS ISSUED Number of bills issued, million Margin enhancement and strong growth in para-pharmacy sales: Para-pharmacy sales have the strongest margins and the share of para-pharmacy sales in retail revenue reached 37.6% as of 1Q23 (34.5% as of 1Q22). GEL million GEORGIA CAPITAL Gross profit margin (%) 24.5% 25.5% 25.5% 25.4% 26.0% 29.3% 29.7% 29.9% 25.3 27.1 28.8 Same store growth (%) 27.6 29.0 31.0 7.6 7.6 7.9% 8.5% 9.0% 6.1% 10.6% -0.8% 12.5% -3.2% 782.4 789.9 679.4 614.7 518.6 450.3 -0.3% 198.8 198.3 GEL million 18.9 19.0 19.3 19.4 14.3 16.8 13.4 13.3 2017 2018 2019 2020 2021 2022 1Q22 1Q23 2017 2018 2019 2020 2021 2022 1Q22 1Q23 CASH FLOW HIGHLIGHTS1 1Q22 1Q23 Change y-o-y Number of pharmacies countrywide 270 296 309 353 368 EBITDA¹ Operating cash flow¹ GEL 16.8m GEL 14.6m -13.3% EBITDA to 8.6% Operating leverage¹(%) NMF 7.8% EBITDA margin¹ (%) 10.1% 4.1% -1.4% -6.7% -7.8% 5.1% -0.5% 2.0 1.6 10.6% 10.4% 9.7% 9.7% 10.4% 10.3% cash 81.5% 71.0% -10.5ppts conversion¹ Free cash flow¹ GEL -2.0m GEL 19.5m NMF GEL million 76.2 76.9 -0.5% 65.3 70.4 52.2 38.9 GEL million 20.6 20.5 Georgia Capital PLC | 1. Excluding IFRS16 impact. NET DEBT & NET DEBT TO LTM EBITDA¹ 1.0 0.6 83.1 77.7 0.4 64.8 0.2 0.2 0.2 39.3 33.4 14.3 20.7 16.9 2017 2018 2019 2020 2021 2022 1Q22 1Q23 2017 2018 2019 2020 2021 2022 1Q22 1Q23 5

View entire presentation